April 4, 2023
Eisai said on April 3 that it will offer its EZH2 inhibitor Tazverik (tazemetostat) free-of-charge to the National Cancer Center for its investigator-led clinical study to be conducted under the “patient-proposed” mixed care scheme. The two partners signed a collaboration...read more